NCOA2, nuclear receptor coactivator 2, 10499

N. diseases: 95; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 Biomarker disease BEFREE A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. 9558366 1998
CUI: C0085669
Disease: Acute leukemia
Acute leukemia 		0.030 AlteredExpression disease BEFREE The MOZ-TIF2 fusion is one of a new family of chromosomal rearrangements that associate HAT activity, transcriptional coactivation, and acute leukemia. 9731070 1998
CUI: C0023464
Disease: Acute biphenotypic leukemia
Acute biphenotypic leukemia 		0.020 GeneticVariation disease BEFREE Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. 9731070 1998
CUI: C2826025
Disease: Mixed phenotype acute leukemia
Mixed phenotype acute leukemia 		0.020 GeneticVariation disease BEFREE Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. 9731070 1998
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 Biomarker disease BEFREE Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). 10459350 1999
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia 		0.010 Biomarker disease BEFREE Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). 10459350 1999
CUI: C0007124
Disease: Noninfiltrating Intraductal Carcinoma
Noninfiltrating Intraductal Carcinoma 		0.010 AlteredExpression disease BEFREE The expression levels of ER-alpha, TIF2, and CBP were significantly higher in the intraductal carcinomas than those in the normal mammary glands. 10690532 2000
CUI: C0020676
Disease: Hypothyroidism
Hypothyroidism 		0.010 AlteredExpression disease BEFREE To examine this hypothesis, we cloned rat complementary DNA fragments corresponding to coactivators (SRC1, TIF2 and TRAM1) and corepressors (N-CoR and SMRT), and studied the ontogenic changes in their corresponding messenger RNAs in rat cerebellum of normal and hypothyroid rats during postnatal development, using a RNase protection assay. 10803578 2000
CUI: C0023418
Disease: leukemia
leukemia 		0.060 GeneticVariation disease BEFREE This similarity is also apparent at the molecular genetic level, in-as-much as the MOZ gene in 8p11 is rearranged in both the translocation and the inversion; in t(8;16)-positive leukemia, a MOZ-CBP chimeric gene is generated, whereas inv(8) has been shown to generate a MOZ-TIF2 fusion gene. 11342350 2000
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.050 GeneticVariation disease BEFREE This similarity is also apparent at the molecular genetic level, in-as-much as the MOZ gene in 8p11 is rearranged in both the translocation and the inversion; in t(8;16)-positive leukemia, a MOZ-CBP chimeric gene is generated, whereas inv(8) has been shown to generate a MOZ-TIF2 fusion gene. 11342350 2000
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 Biomarker disease CTD_human The three coactivators, TIF-2, SRC-1 and RAC3, are up-regulated in relapsed prostate cancer. 12237244 2002
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 AlteredExpression disease BEFREE The three coactivators, TIF-2, SRC-1 and RAC3, are up-regulated in relapsed prostate cancer. 12237244 2002
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.310 Biomarker group CTD_human Androgen receptors in prostate cancer. 12237244 2002
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 AlteredExpression disease BEFREE The three coactivators, TIF-2, SRC-1 and RAC3, are up-regulated in relapsed prostate cancer. 12237244 2002
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.040 GeneticVariation disease BEFREE MOZ-linked fusion proteins such as MOZ-CBP (CREB binding protein), MOZ-TIF2 (transcriptional intermediary factor 2), and MOZ-p300 (adenoviral E1A-associated protein) are associated with AML chromosomal abnormalities at t(8;16)(p11;p13), inv(8)(p11q13), and t(8;22)(p11;q13), respectively, and are thought to account for leukemogenesis occurring through the aberrant regulation of histone acetylation. 12619166 2003
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 Biomarker disease BEFREE Here we demonstrate that MOZ-TIF2 has transforming properties in vitro and causes AML in a murine bone marrow transplant assay. 12676584 2003
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 Biomarker disease LHGDN Here we demonstrate that MOZ-TIF2 has transforming properties in vitro and causes AML in a murine bone marrow transplant assay. 12676584 2003
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.040 Biomarker disease BEFREE These results indicate that nucleosomal targeting by MOZ and recruitment of CBP by TIF2 are critical requirements for MOZ-TIF2 transformation and indicate that MOZ gain of function contributes to leukemogenesis. 12676584 2003
CUI: C0023479
Disease: Acute myelomonocytic leukemia
Acute myelomonocytic leukemia 		0.010 GeneticVariation disease BEFREE A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. 12964013 2003
CUI: C0279627
Disease: Adult Acute Myelomonocytic Leukemia
Adult Acute Myelomonocytic Leukemia 		0.010 GeneticVariation disease BEFREE A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. 12964013 2003
CUI: C0279644
Disease: Childhood Acute Myelomonocytic Leukemia
Childhood Acute Myelomonocytic Leukemia 		0.010 GeneticVariation disease BEFREE A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. 12964013 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.310 Biomarker group LHGDN Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. 14662770 2004
CUI: C0334070
Disease: Maturation defect
Maturation defect 		0.010 Biomarker phenotype BEFREE Interestingly, the overall abnormal features displayed by the SRC-1(+/-)/TIF2(-/-) and SRC-1(-/-)/TIF2(-/-) mutant testes, including spermatid maturation defects, increase in Sertoli cell lipid stores, loss of immature germ cells, and formation of giant multinucleated spermatids, are commonly detected in testes of elderly men, suggesting that deficiencies in molecular pathways involving TIF2 and SRC-1 in Sertoli cells could participate in testicular senescence. 15070739 2004
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Increases in copy numbers of the LAMC2, TGFB2, and AKT3 genes (located on 1q) and decreases in copy numbers of FGR/SRC2 and CYLD (located on 1p and 16q, respectively) were observed in more than 30% of tumors, including small, well-differentiated carcinomas. 15133472 2004
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 Biomarker disease BEFREE The potential resulting chimaeric proteins showed similarities with MYST3-CBP, MYST3-P300 and MYST3-NCOA2 putative fusion proteins found in other cases of AML. 15147375 2004